Patents Assigned to Applied Molecular Evolution, Inc.
-
Patent number: 11180549Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.Type: GrantFiled: December 17, 2019Date of Patent: November 23, 2021Assignees: Janssen Biotech, Inc., Applied Molecular Evolution, IncInventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
-
Publication number: 20140099311Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: ApplicationFiled: December 4, 2013Publication date: April 10, 2014Applicants: Applied Molecular Evolution, Inc., Janssen Biotech, Inc.Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
-
Patent number: 8623365Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: GrantFiled: December 21, 2011Date of Patent: January 7, 2014Assignee: Applied Molecular Evolution, Inc.Inventors: Julian Davies, Ying Tang, Jeffry Dean Watkins
-
Publication number: 20120114560Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: ApplicationFiled: December 21, 2011Publication date: May 10, 2012Applicant: APPLIED MOLECULAR EVOLUTION, INC.Inventors: Julian DAVIES, Ying TANG, Jeffry Dean WATKINS
-
Patent number: 8153125Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: May 20, 2004Date of Patent: April 10, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Jeffry D. Watkins, Julian Davies, David M. Marquis, Barrett W Allan, Brian Ondek
-
Patent number: 8105597Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: GrantFiled: July 17, 2009Date of Patent: January 31, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Julian Davies, Ying Tang, Jeffry Dean Watkins
-
Patent number: 8067003Abstract: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.Type: GrantFiled: October 8, 2010Date of Patent: November 29, 2011Assignees: Centocor, Inc., Applied Molecular Evolution, Inc.Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
-
Publication number: 20100239574Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: ApplicationFiled: February 17, 2010Publication date: September 23, 2010Applicants: MEDIMMUNE, LLC, APPLIED MOLECULAR EVOLUTION, INC.Inventors: JAMES F. YOUNG, LESLIE S. JOHNSON, WILLIAM D. HUSE, HERREN WU, JEFFRY D. WATKINS
-
Patent number: 7740847Abstract: The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.Type: GrantFiled: July 18, 2005Date of Patent: June 22, 2010Assignee: Applied Molecular Evolution, Inc.Inventors: Barrett Allan, Weidong Jiang, Ying Tang, Jeffry Dean Watkins
-
Patent number: 7723484Abstract: The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.Type: GrantFiled: November 6, 2006Date of Patent: May 25, 2010Assignee: Applied Molecular Evolution, Inc.Inventors: Catherine Brautigam Beidler, Alain Philippe Vasserot, Jeffry Dean Watkins
-
Patent number: 7667007Abstract: The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to ?v?3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of ?v?3 by contacting ?v?3 with an enhanced LM609 grafted antibody.Type: GrantFiled: April 14, 2008Date of Patent: February 23, 2010Assignee: Applied Molecular Evolution, Inc.Inventors: William D. Huse, Herren Wu
-
Patent number: 7560112Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: April 28, 2006Date of Patent: July 14, 2009Assignees: Applied Molecular Evolution, Inc., Centocor Ortho Biotech Inc.Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
-
Patent number: 7541033Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.Type: GrantFiled: January 21, 2004Date of Patent: June 2, 2009Assignee: Applied Molecular Evolution, Inc.Inventors: Craig Duane Dickinson, Alain Philippe Vasserot, Jeffry Dean Watkins, Jirong Lu
-
Publication number: 20090023900Abstract: The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to ?v?3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of ?v?3 by contacting ?v?3 with an enhanced LM609 grafted antibody.Type: ApplicationFiled: April 14, 2008Publication date: January 22, 2009Applicant: APPLIED MOLECULAR EVOLUTION, INC.Inventors: William D. Huse, Herren Wu
-
Patent number: 7422745Abstract: The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity ?v?3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. The invention additionally provides a high affinity LM609 grafted antibody comprising one or more CDRs having at least one amino acid substitution, where the ?v?3 binding activity of the high affinity LM609 grafted antibody is enhanced. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided.Type: GrantFiled: June 16, 2003Date of Patent: September 9, 2008Assignee: Applied Molecular Evolution, Inc.Inventors: William D. Huse, Scott M. Glaser
-
Patent number: 7422744Abstract: The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to ?v?3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of ?v?3. The method consists of contacting ?v?3 with Vitaxin or a LM609 grafted antibody or functional fragments thereof under conditions which allow binding to ?v?3.Type: GrantFiled: May 30, 2003Date of Patent: September 9, 2008Assignee: Applied Molecular Evolution, Inc.Inventors: William D Huse, Scott M Glaser
-
Publication number: 20080213281Abstract: The invention provides a butyrylchinesterase variant, a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant and a method of treating cancer by administering to an individual an effective amount a butyrylcholinesterase variant exhibiting increased capability to convert a camptothecin derivative to a topoisomerase inhibitor compared to butyrylcholinesterase.Type: ApplicationFiled: December 4, 2003Publication date: September 4, 2008Applicant: Applied Molecular Evolution, Inc. c/o Eli Lilly and Company Patent DivisionInventors: Jeffrey D. Watkins, James D. Pancock
-
Patent number: 7371382Abstract: The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to ?V?3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of ?V?3 by contacting ?V?3 with an enhanced LM609 grafted antibody.Type: GrantFiled: November 25, 2002Date of Patent: May 13, 2008Assignee: Applied Molecular Evolution, Inc.Inventors: William D Huse, Herren Wu
-
Patent number: 6893845Abstract: The invention is directed to a composition of matter consisiting of a plurality of procaryotic cells. The plurality of procaryotic cells contain diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule. The heteromeric receptors being expressed on the surface of filamentous bacteriophage.Type: GrantFiled: June 5, 1995Date of Patent: May 17, 2005Assignee: Applied Molecular Evolution, Inc.Inventor: William D. Huse
-
Publication number: 20050003469Abstract: The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.Type: ApplicationFiled: August 2, 2004Publication date: January 6, 2005Applicant: Applied Molecular Evolution, Inc.Inventors: Jeffry Watkins, William Huse